This article first appeared on GuruFocus.

Eton Pharmaceuticals Inc (NASDAQ:ETON) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $20.47 million, and the earnings are expected to come in at $0.09 per share. The full year 2025's revenue is expected to be $78.50 million, and the earnings are expected to be $0.17 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Signs with ETON.

Is ETON fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Eton Pharmaceuticals Inc (NASDAQ:ETON) have increased from $76.92 million to $78.50 million for the full year 2025. However, they have declined from $112.08 million to $110.56 million for 2026 over the past 90 days. Earnings estimates have decreased from $0.25 per share to $0.17 per share for the full year 2025, and from $1.16 per share to $1.03 per share for 2026 over the past 90 days.

In the previous quarter ending on 2025-06-30, Eton Pharmaceuticals Inc's (NASDAQ:ETON) actual revenue was $18.93 million, which beat analysts' revenue expectations of $16.71 million by 13.27%. Eton Pharmaceuticals Inc's (NASDAQ:ETON) actual earnings were -$0.10 per share, which missed analysts' earnings expectations of -$0.037 per share by -170.27%. After releasing the results, Eton Pharmaceuticals Inc (NASDAQ:ETON) was up by 12.32% in one day.

Based on the one-year price targets offered by 3 analysts, the average target price for Eton Pharmaceuticals Inc (NASDAQ:ETON) is $30.00 with a high estimate of $35.00 and a low estimate of $26.00. The average target implies an upside of 62.60% from the current price of $18.45.

Based on GuruFocus estimates, the estimated GF Value for Eton Pharmaceuticals Inc (NASDAQ:ETON) in one year is $16.40, suggesting a downside of -11.11% from the current price of $18.45.

Based on the consensus recommendation from 3 brokerage firms, Eton Pharmaceuticals Inc's (NASDAQ:ETON) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.